Skip to main content
. 2019 Jun 28;23(8):5588–5599. doi: 10.1111/jcmm.14457

Figure 1.

Figure 1

Systemic delivery of Bry‐1 ameliorated experimental colitis in Il‐10 −/− mice. (A) Bry‐1‐treated Il‐10 −/− mice showed lower mean disease activity index values than untreated Il‐10 −/− mice beginning at the third week after drug administration. (C) The systemic delivery of Bry‐1 significantly improved the histological manifestations of chronic colitis (representative H&E staining; scale bar: 100 μmol/L). The histological inflammation score (B) was clearly improved in tissue from Bry‐1‐treated Il‐10 −/−mice compared with that from untreated Il‐10 −/− mice. Both the protein (D) and mRNA (E) levels of IFN‐γ, TNF‐α and IL‐17A were significantly lower in the colonic tissue from Bry‐1‐treated Il‐10 −/− mice than that from untreated Il‐10 −/− mice. Bry‐1, Bryostatin‐1; WT, wild‐type; IL‐17A, interleukin 17A; IFN‐γ, interferon‐γ; TNF‐α, tumour necrosis factor‐α; and NS, no significance. At least three independent experiments with six to eight mice in each group were performed, with one representative experiment is shown. The data are expressed as the mean ± SD. ▼ P < 0.05